title: Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes.
abstract: Serotonin (5-HT(2)) antagonists show high affinity for the alpha(1)-adrenoceptor (alpha(1)-AR) in addition to the 5-HT(2) receptor. In the present study we compared the pharmacological characteristics of a new 5-HT(2) antagonist sarpogrelate and its active metabolite M-1 with those of ketanserin on human recombinant alpha(1)-AR subtypes. In the binding study, sarpogrelate, M-1 and ketanserin produced concentration-dependent inhibition of (3)H-prazosin binding to alpha(1)-ARs. Among the three drugs, ketanserin showed the highest affinity for alpha(1a)-, alpha(1b)- and alpha(1d)-ARs (pKi 8.0, 8.3 and 7.6, respectively). Sarpogrelate had a relatively low affinity for the three subtypes (6.3, 6.4 and 6.3, respectively) and M-1 showed medium affinity (7.1, 7.1 and 6.1, respectively). Chinese hamster ovary (CHO) cells expressing each alpha(1)-AR subtype showed concentration-dependent inositol phosphate (IP) accumulation in response to phenylephrine. The concentration response curves were shifted to the right by three drugs, and the pKb values were close to the pKi values in the binding study. In addition to these effects, sarpogrelate and M-1, but not ketanserin produced an increase in the basal IP level of alpha(1d)-expressed CHO cells, although the increase was less than that of phenylephrine. The present results indicate that sarpogrelate and M-1 have antagonistic activity to the three alpha(1)-AR subtypes, but their affinities are significantly lower than those of ketanserin.
authors.affiliation: Department of Pharmacology, School of Medicine, Fukui Medical University, Matsuoka, Japan.
authors.forename: Malika
authors.initials: M
authors.lastname: Israilova
authors.forename: Fumiko
authors.initials: F
authors.lastname: Suzuki
authors.forename: Takashi
authors.initials: T
authors.lastname: Tanaka
authors.forename: Takafumi
authors.initials: T
authors.lastname: Nagatomo
authors.forename: Takanobu
authors.initials: T
authors.lastname: Taniguchi
authors.forename: Ikunobu
authors.initials: I
authors.lastname: Muramatsu
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D016466:CHO Cells; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D015870:Gene Expression; D006801:Humans; D007650:Ketanserin / Q000378:metabolism* / Q000494:pharmacology; D010656:Phenylephrine / Q000378:metabolism / Q000494:pharmacology; D011224:Prazosin / Q000378:metabolism; D011412:Propanolamines / Q000378:metabolism* / Q000494:pharmacology; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000378:metabolism* / Q000494:pharmacology; D013386:Succinates / Q000378:metabolism* / Q000494:pharmacology; D014316:Tritium
chemical_list: D000316:Adrenergic alpha-Agonists; D011412:Propanolamines; D018340:Receptors, Adrenergic, alpha-1; D012702:Serotonin Antagonists; D013386:Succinates; D014316:Tritium; C099060:1-(2-(3-methoxyphenyl)ethyl)phenoxy-3-(dimethylamino)-2-propanol; C064294:sarpogrelate; D010656:Phenylephrine; D007650:Ketanserin; D011224:Prazosin